Skip to main content
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.
What are you looking for?

Time to approval for Chimeric Antigen Receptor T-cells (CAR-T) therapies among Nordic Countries

Post-acute COVID-19 syndrome, also re

Chimeric Antigen Receptor-T Cell (CAR-T) therapy is a cell-based gene therapy designed to attack cancer cell antigens, specifically in patients with relapsed/refractory (R/R) B-cell malignancies. To date, six CAR-T therapies have been approved by the European Medicines Agency (EMA) across different indications.

This poster, presented at ISPOR 2023, examined the time to approval for six CAR-T therapies in four Nordic countries (Denmark, Finland, Norway and Sweden), after authorization by the EMA.

Interested in Syneos Health?